The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
Authors
Keywords
-
Journal
World Journal of Surgical Oncology
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-03
DOI
10.1186/s12957-020-01933-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
- (2019) Neal Ready et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
- (2019) Celeste Lebbé et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. CANCER CELL
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitors for hepatocellular carcinoma
- (2019) Imane El Dika et al. CANCER
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma
- (2019) Sophia Kreft et al. EUROPEAN JOURNAL OF CANCER
- Combination of CTLA-4 and PD-1 blockers for treatment of cancer
- (2019) Anand Rotte JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer
- (2019) Shannon Cope et al. Journal of Comparative Effectiveness Research
- Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
- (2019) Valerie Glutsch et al. Journal for ImmunoTherapy of Cancer
- Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data
- (2019) Morganna Freeman et al. ADVANCES IN THERAPY
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer
- (2019) Hidetoshi Hayashi et al. International Journal of Clinical Oncology
- Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios
- (2019) Bulent Cetin et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy
- (2019) Michael A. Morse et al. ONCOLOGIST
- Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab
- (2019) Ning Shao et al. MEDICAL SCIENCE MONITOR
- Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
- (2019) François Ghiringhelli et al. Frontiers in Immunology
- Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
- (2019) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
- (2019) Neal E. Ready et al. Journal of Thoracic Oncology
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Immune checkpoint blockade in small cell lung cancer
- (2019) Rebecca Y. Tay et al. LUNG CANCER
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
- (2018) Georgina V Long et al. LANCET ONCOLOGY
- Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
- (2018) Izabela Lasinska et al. Anti-Cancer Agents in Medicinal Chemistry
- Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine
- (2018) Ahmad Tarhini et al. CANCER TREATMENT REVIEWS
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
- (2018) Gideon M. Blumenthal et al. Journal of Thoracic Oncology
- Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
- (2018) David F. McDermott et al. QUALITY OF LIFE RESEARCH
- Role of immunotherapy in stage III nonsmall cell lung cancer
- (2018) Anna Wrona CURRENT OPINION IN ONCOLOGY
- Immunotherapy in patients with early stage resectable nonsmall cell lung cancer
- (2018) Katrien Ghysen et al. CURRENT OPINION IN ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers
- (2018) Ying L. Liu et al. Current Oncology Reports
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Immunotherapy for advanced melanoma: future directions
- (2016) Sara Valpione et al. Immunotherapy
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Safety of immune checkpoint inhibitors in Chinese patients with melanoma
- (2016) Xizhi Wen et al. MELANOMA RESEARCH
- Immunotherapy of melanoma: Present options and future promises
- (2015) Anand Rotte et al. CANCER AND METASTASIS REVIEWS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started